{"title":"概述:灵活多变的工业质量设计和过程分析技术方法","authors":"Razia Kutty, Machindra Nikam, Sakshi Chaudhari, Chetana Shinde, Priya Gadakh, Pooja Niphade, Amit Kakad","doi":"10.18231/j.jpbs.2023.014","DOIUrl":null,"url":null,"abstract":"Quality by Design (QbD) is crucial to the creation of contemporary in pharmaceuticals, microbiology, biotechnology, product management etc. In order to build proactive, scientific, and risk-based processes and products, QbD helps and supports both the industry and the FDA. Instead of waiting until the final quality check of the finished product, it is founded on the idea of establishing quality from the very beginning of the process. A successful plan that lowers batch failures and recalls is finally provided by an efficient QbD approach, which offers insights and crucial upstream information throughout the development process. The purpose of this review is to provide an overview of the implementation of Quality by Design (QbD), its tools, elements, and techniques, the relevancy with various guidelines, and the use in present-day pharmaceutical. The IQ Consortium provides information on the current situation of process analytical technology (PAT) as it relates to the creation of active pharmaceutical ingredients (API) in branded pharmaceutical firms. The article gives concrete examples of why and how the pharmaceutical industry uses PAT tools in API development by using an API process pipeline. PAT can reduce personnel risks involved with sampling dangerous compounds for in-process testing and increase R&D efficiency. Although not all chemical processes or stages are easily suited to applying the features of the PAT toolbox, PAT permits accurate and speedy (real or near time) evaluations of processes that might involve compounds that are highly dangerous, transitory, or heterogeneous when necessary. The major regulatory agencies and the biotech sector have worked hard to assist the application of the ideas of Quality by Design (QbD) and Process Analytical Technology (PAT) over the past ten years, with varying degrees of success. Despite the fact that just one biotech therapy has received approval under the QbD paradigm thus far, the tools and methods associated with these two ideas are deeply ingrained in the work procedures of the majority of international pharmaceutical firms. This overview is mainly focused on the QbD and PAT's development in the first place. Second, give an overview of QbD and PAT implementation and point out any places where more contributions are possible.","PeriodicalId":517289,"journal":{"name":"Journal of Pharmaceutical and Biological Sciences","volume":"695 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Overview: flexible and versatile approach of quality by design & process analytical technology in industries\",\"authors\":\"Razia Kutty, Machindra Nikam, Sakshi Chaudhari, Chetana Shinde, Priya Gadakh, Pooja Niphade, Amit Kakad\",\"doi\":\"10.18231/j.jpbs.2023.014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Quality by Design (QbD) is crucial to the creation of contemporary in pharmaceuticals, microbiology, biotechnology, product management etc. In order to build proactive, scientific, and risk-based processes and products, QbD helps and supports both the industry and the FDA. Instead of waiting until the final quality check of the finished product, it is founded on the idea of establishing quality from the very beginning of the process. A successful plan that lowers batch failures and recalls is finally provided by an efficient QbD approach, which offers insights and crucial upstream information throughout the development process. The purpose of this review is to provide an overview of the implementation of Quality by Design (QbD), its tools, elements, and techniques, the relevancy with various guidelines, and the use in present-day pharmaceutical. The IQ Consortium provides information on the current situation of process analytical technology (PAT) as it relates to the creation of active pharmaceutical ingredients (API) in branded pharmaceutical firms. The article gives concrete examples of why and how the pharmaceutical industry uses PAT tools in API development by using an API process pipeline. PAT can reduce personnel risks involved with sampling dangerous compounds for in-process testing and increase R&D efficiency. Although not all chemical processes or stages are easily suited to applying the features of the PAT toolbox, PAT permits accurate and speedy (real or near time) evaluations of processes that might involve compounds that are highly dangerous, transitory, or heterogeneous when necessary. The major regulatory agencies and the biotech sector have worked hard to assist the application of the ideas of Quality by Design (QbD) and Process Analytical Technology (PAT) over the past ten years, with varying degrees of success. Despite the fact that just one biotech therapy has received approval under the QbD paradigm thus far, the tools and methods associated with these two ideas are deeply ingrained in the work procedures of the majority of international pharmaceutical firms. This overview is mainly focused on the QbD and PAT's development in the first place. Second, give an overview of QbD and PAT implementation and point out any places where more contributions are possible.\",\"PeriodicalId\":517289,\"journal\":{\"name\":\"Journal of Pharmaceutical and Biological Sciences\",\"volume\":\"695 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical and Biological Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.jpbs.2023.014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical and Biological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.jpbs.2023.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
质量源于设计(QbD)对制药、微生物学、生物技术、产品管理等领域的当代创造至关重要。为了建立积极、科学、基于风险的流程和产品,QbD 为制药业和美国食品及药物管理局提供了帮助和支持。QbD 建立在从流程一开始就确立质量的基础上,而不是等到成品的最终质量检查。高效的 QbD 方法可在整个开发过程中提供洞察力和重要的上游信息,最终提供一个成功的计划,减少批次失败和召回。本综述旨在概述质量源于设计(QbD)的实施、其工具、要素和技术、与各种指导方针的相关性以及在当今制药业中的应用。IQ Consortium 提供了有关工艺分析技术 (PAT) 现状的信息,因为它与品牌制药公司生产活性药物成分 (API) 有关。文章举例说明了制药行业在原料药开发过程中使用原料药工艺管道的原因和方法。PAT 可以降低对危险化合物取样进行过程中测试所涉及的人员风险,并提高研发效率。虽然并非所有化学工艺或阶段都能轻松应用 PAT 工具箱的功能,但 PAT 可以在必要时对可能涉及高危险性、短暂性或异质性化合物的工艺进行准确、快速(实时或近实时)的评估。在过去的十年中,主要监管机构和生物技术部门一直在努力协助质量源于设计(QbD)和工艺分析技术(PAT)理念的应用,并取得了不同程度的成功。尽管迄今为止只有一种生物技术疗法在 QbD 范式下获得批准,但与这两种理念相关的工具和方法已深深扎根于大多数国际制药公司的工作程序中。本综述首先主要介绍 QbD 和 PAT 的发展。其次,概述 QbD 和 PAT 的实施情况,并指出可能做出更多贡献的地方。
Overview: flexible and versatile approach of quality by design & process analytical technology in industries
Quality by Design (QbD) is crucial to the creation of contemporary in pharmaceuticals, microbiology, biotechnology, product management etc. In order to build proactive, scientific, and risk-based processes and products, QbD helps and supports both the industry and the FDA. Instead of waiting until the final quality check of the finished product, it is founded on the idea of establishing quality from the very beginning of the process. A successful plan that lowers batch failures and recalls is finally provided by an efficient QbD approach, which offers insights and crucial upstream information throughout the development process. The purpose of this review is to provide an overview of the implementation of Quality by Design (QbD), its tools, elements, and techniques, the relevancy with various guidelines, and the use in present-day pharmaceutical. The IQ Consortium provides information on the current situation of process analytical technology (PAT) as it relates to the creation of active pharmaceutical ingredients (API) in branded pharmaceutical firms. The article gives concrete examples of why and how the pharmaceutical industry uses PAT tools in API development by using an API process pipeline. PAT can reduce personnel risks involved with sampling dangerous compounds for in-process testing and increase R&D efficiency. Although not all chemical processes or stages are easily suited to applying the features of the PAT toolbox, PAT permits accurate and speedy (real or near time) evaluations of processes that might involve compounds that are highly dangerous, transitory, or heterogeneous when necessary. The major regulatory agencies and the biotech sector have worked hard to assist the application of the ideas of Quality by Design (QbD) and Process Analytical Technology (PAT) over the past ten years, with varying degrees of success. Despite the fact that just one biotech therapy has received approval under the QbD paradigm thus far, the tools and methods associated with these two ideas are deeply ingrained in the work procedures of the majority of international pharmaceutical firms. This overview is mainly focused on the QbD and PAT's development in the first place. Second, give an overview of QbD and PAT implementation and point out any places where more contributions are possible.